Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study

Br J Haematol. 2010 Jan;148(2):332-4. doi: 10.1111/j.1365-2141.2009.07930.x. Epub 2009 Oct 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Benzoates / therapeutic use*
  • Deferasirox
  • Female
  • Ferritins / blood
  • Heart
  • Humans
  • Iron Chelating Agents / therapeutic use*
  • Liver / pathology
  • Magnetic Resonance Imaging / methods
  • Male
  • Middle Aged
  • Myocardium / pathology
  • Pilot Projects
  • Prospective Studies
  • Treatment Outcome
  • Triazoles / therapeutic use*
  • beta-Thalassemia / drug therapy*

Substances

  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Ferritins
  • Deferasirox